BOSTON--(BUSINESS WIRE)--Acetylon Pharmaceuticals Inc., the leader in the development of next generation selective HDAC inhibitors to epigenetically regulate protein and gene function for the treatment of cancers and severe chronic diseases, today announced that Walter C. Ogier, President and Chief Executive Officer of Acetylon, will participate in two investor conferences during September, including the following:
